Population Health Management during Student Pharmacist Introductory Experiential Education to Expand Clinical Pharmacist Impact by McConnell, Macy et al.
Original Research PHARMACY PRACTICE 
 
http://z.umn.edu/INNOVATIONS                         2019, Vol. 10, No. 4, Article 9                       INNOVATIONS in pharmacy                                                                              DOI: https://doi.org/10.24926/iip.v10i4.2231 1 
 
Population Health Management during Student Pharmacist Introductory Experiential 
Education to Expand Clinical Pharmacist Impact 
Macy McConnell, PharmD1,2; Daniel J. Mobley, PharmD1,2,4; Alex Gidal, PharmD1,2,5; Michael W. Nagy, PharmD1,3,5 
1William S. Middleton Memorial Veteran Affairs Hospital; 2University of Wisconsin-Madison School of Pharmacy; 
3Medical College of Wisconsin School of Pharmacy; 4VA Puget Sound Health Care System; 5Clement J. Zablocki Veterans Affairs 
Medical Center 
 
Abstract  
Objective: To evaluate the impact of incorporating pre-advanced pharmacy practice experience (pre-APPE) student pharmacists into 
three different population health management (PHM) projects.  
Methods: The prospective quality improvement projects incorporated three third-year student pharmacists who developed and 
conducted individual PHM projects over the course of three to seven months. The projects included hypoglycemia screening, hepatitis 
C virus and human immunodeficiency virus screening, and statin use evaluations for atherosclerotic cardiovascular disease risk 
reduction. Under the guidance of a clinical pharmacist, students developed project materials, conducted patient chart reviews, and 
contacted patients to make interventions such as recommendations for therapy, ambulatory patient monitoring, patient education, 
and arranging provider follow-up. Student impact was evaluated through the number of patients screened, the number of eligible 
patients contacted, and the total number of interventions or recommendations made. Student time spent was tracked throughout 
the projects. 
Results: Out of 244 patients screened, 198 patients met inclusion criteria and 162 patients were contacted or assessed by a student 
pharmacist. Students made a total of 319 interventions, including patient education (132), patient monitoring (132), 
pharmacotherapy recommendations (28), and arranging follow-up (27). On average students screened 33 patients per month, and, 
per patient, required 8.6 minutes for eligibility assessment and approximately 6 minutes for telephone interviews. 
Conclusion: This report demonstrates that pre-APPE student pharmacists are well-equipped to design and implement PHM projects. 
Utilization of student pharmacists in similar PHM programs can expand the pharmacist’s impact on patient care in the ambulatory 
care setting. 
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Introduction 
How can an organization leverage student pharmacists’ skill 
sets to improve the health of the population served? As 
population health management (PHM) cements itself as a core 
component in healthcare, pharmacists need to effectively 
address this question to improve student pharmacists’ 
education and the health of the population they serve. In 
essence, PHM is a proactive approach that identifies and 
executes interventions for patients at high risk of poor health 
outcomes based on a well-defined clinical parameter.1 
  
The United States will experience an estimated shortage of 
21,100 to 55,200 primary care physicians by 2032.2 This 
shortage risks worsening healthcare access and quality for 
patients. Clinical pharmacists, however, are well positioned to 
mitigate the potential effects of this shortage and improve the 
triple aim of healthcare developed and defined by the Institute  
for Healthcare Improvement as (1) improving the experience 
of care, (2) improving the health of populations, and (3)  
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reducing the per capita healthcare costs.3 When incorporated 
into primary care teams, clinical pharmacists are a valuable 
resource for PHM, often addressing each aspect of the triple 
aim. For example, Altavela et al created a practice model 
focusing on complex and resource intensive patients, and 
clinical pharmacist involvement demonstrated a 42% decrease 
in 30-day readmission rates and a 20% decrease in annual 
medical charges.4 Carmichael and colleagues utilized 
electronic health record (EHR) data within the Veterans Health 
Administration (VHA) to identify patients failing to meet 
healthcare effectiveness data and information set (HEDIS) 
measures.5 Data gathered from the EHR was compiled into an 
interactive “dashboard” which allowed clinical pharmacists to 
proactively contact applicable patients resulting in over 5,000 
additional screenings of patients for hepatitis C virus (HCV), as 
well as a 5% increase in timely hemoglobin A1c measurements 
in patients at risk for hypoglycemia.  
 
While healthcare systems have identified the value clinical 
pharmacists bring to PHM, ways to train student pharmacists 
for an active role in PHM are still under development.6 
Including PHM as a part of pharmacy training encourages 
students to become involved in PHM in their professional 
practice.7 Population health management is a recommended 
component of pharmacy education by the Accreditation 
Council for Pharmacy Education (ACPE) and the Center for the 
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Advancement of Pharmacy Education (CAPE).8,9 The American 
Association of Colleges of Pharmacy established core 
Entrustable Professional Activities (EPAs) in which new 
pharmacy graduates should attain competence prior to 
entering the workforce.10 One EPA domain, “population health 
promoter,” includes: identifying patients at risk for prevalent 
diseases in a population, minimizing adverse drug events and 
medication errors, and maximizing the appropriate use of 
medications in a population. 
  
Though coverage of population-based healthcare has 
expanded in the didactic pharmacy curricula, few reports have 
described incorporating pharmacy learners in practicing PHM 
in experiential settings.7 Cannon et al incorporated 46 
students in advanced pharmacy practice experience (APPE) 
rotations to assess non-adherence and the need for renal dose 
adjustments, leading to 3,774 interventions over four years.11 
In another example, Kaminetzky and colleagues leveraged 
pharmacy, medicine, and nurse practitioner residents in an 
interdisciplinary PHM focused training curriculum 
concentrating on chronic disease state management, which 
improved PHM skills and increased pharmacy resident 
confidence in conducting PHM.12 Whether woven into an APPE 
rotation or a year-long post-graduation residency program, 
practical experience of PHM was mutually beneficial for 
pharmacy trainees’ education and clinical pharmacists’ 
workload capacity. Leveraging the time and energy of student 
pharmacists to assist in the completion of PHM could enhance 
the ability of primary care teams to fulfill the triple aim. 
  
This report focused on incorporating third-year student 
pharmacists in different PHM projects. The primary objective 
was to evaluate the impact student pharmacists had on the 
respective clinics by examining the number of patients 
screened, the number of eligible patients contacted, and the 
total number of interventions or recommendations made. 
Student time spent was tracked throughout the projects. 
 
Methods 
The prospective quality improvement projects incorporated 
three third-year student pharmacists into the workflow for 
PHM within outpatient clinics of a VHA medical center. Clinical 
pharmacists within the outpatient clinics were integrated 
within patient-aligned care teams (PACTs), which included 
primary care providers (PCP), nurse care managers, social 
workers, and other specialized healthcare providers. Under 
the PACT model, clinical pharmacists operated under a scope 
of practice, which granted them prescriptive authority and 
laboratory ordering privileges for management of any chronic 
disease including, but not limited to, diabetes, hypertension, 
and hyperlipidemia. They were also closely involved in 
teaching and precepting student pharmacists. Thus, the PACT 
model offered a unique opportunity for student pharmacists 
to be directly involved with PHM. 
 
Student PHM projects included a hypoglycemia screening in 
accordance with the VHAs hypoglycemia safety initiative (HSI), 
HCV and human immunodeficiency virus (HIV) screening, and 
statin use evaluations for atherosclerotic cardiovascular 
disease risk reduction (ASCVD).13-15 Projects were developed 
by student pharmacists in accordance with the most up-to-
date clinical guidelines and in collaboration with a clinical 
pharmacist preceptor. Student pharmacists were employees 
of the VHA medical center prior to project implementation; 
however, selection and participation in the quality 
improvement projects were on a voluntary basis. Students 
worked independently of one another to create materials for 
each project, including data collection sheets, phone scripts 
for speaking with patients, and note templates for 
documenting patient encounters and recommendations within 
the EHR. Specific project designs can be found in Table 1. All 
project materials were reviewed by the clinical pharmacist 
preceptor with feedback provided for quality improvement. 
 
Student pharmacists were oriented to the EHR system prior to 
project implementation. Additional training was provided over 
the course of the data collection period as necessary. Eligible 
patients for each project were identified utilizing a 
computerized algorithm and the EHR generated patient 
dashboards based on pre-selected inclusion and exclusion 
criteria (Table 1). Each student conducted chart reviews and 
discussed eligible patients with a pharmacist preceptor. In the 
HSI and HCV projects, students contacted patients via 
telephone and made interventions including 
recommendations for therapy, ambulatory patient monitoring, 
patient education, and arranging provider follow-up (Table 1). 
Specifically, in the HSI project, pharmacotherapy 
recommendations were made to the patient’s PACT 
pharmacist and patient education was provided on acute 
hypoglycemia identification and self-management. In contrast, 
the student pharmacist for the ASCVD project assessed 
patients for statin eligibility and made recommendations for 
initiation of statin medication and follow-up to the patient’s 
PCP. A pharmacist preceptor co-signed all student pharmacist 
notes in the EHR and provided feedback for quality 
improvement regarding patient interactions and 
documentation. Descriptive statistics were used to evaluate 
each project. These projects were not considered as 
constituting research as defined under 45 CFR 46.102(d).  
 
Results 
A total of 244 patients were identified through the EHR 
dashboards (Figure 1). Of these, 198 (81%) patients met 
inclusion criteria across all projects and 162 (66%) were 
ultimately contacted or assessed by a student pharmacist. 
Throughout the project periods, a total of 319 interventions 
occurred involving multiple PCPs from three outpatient clinics 
(Table 2).  
 
Of the patients who received direct communication from a 
student pharmacist (n = 135), 132 (97.8%) received 
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ambulatory patient monitoring of new objective data and 
patient education (Table 2). Monitoring in the HCV project 
resulted in one positive screening for HCV (1/110, 0.91%) and 
no positive screenings for HIV (0/40, 0%). The HSI project 
intervened on four instances of clinical hypoglycemia (4/25, 
16%). 
 
Twenty-eight recommendations were made to adjust 
pharmacotherapy after patient interview or assessment and 
discussion with a pharmacist preceptor (Table 2). Follow-up 
was arranged in all three projects for 27 (16.7%) patients. All 
patients screening positive for HCV or hypoglycemia had  
follow-up arranged with a PACT team member. 
 
On average 8.6 minutes were required to assess patients for 
eligibility as well as prepare for screening prior to patient 
contact. Approximately 1,500 minutes (25 hours) were spent 
reviewing patient charts over the entire course of all projects. 
Time spent talking with patients for the HCV and HSI projects 
totaled 790 minutes with less than 6 minutes spent per 
patient on average. The average monthly number of patients 
screened was approximately eight in the HSI project, nine in 
the ASCVD project, and 16 in the HCV project. 
 
Discussion 
These projects demonstrated the utility of incorporating 
student pharmacists in PHM through the large number of 
patients screened, interventions made, and potential 
increased clinical pharmacist impact. The interventions made 
by students included engaging patients in screening for 
infectious diseases, evaluating patient’s self-management of 
care, providing education, and identifying drug related 
problems with appropriate follow-up. The HCV and HSI 
projects revealed previously undetected HCV infection and 
clinical hypoglycemia respectively, while the ASCVD project 
identified 75% of patients as eligible for a statin. Students 
demonstrated the capability of conducting PHM while using 
critical thinking skills to propose resolutions to clinical 
problems. 
 
Student pharmacists have the clinical knowledge and skill set 
needed to address unique disease states in PHM, such as HCV 
screening, hypoglycemia identification and education, and 
appropriate statin prescribing. These PHM topics were 
selected based on complexity to match student pharmacist 
knowledge and clinical skills to allow for practical application 
with guided practice. To our knowledge this is the first report 
incorporating pre-APPE students into PHM during experiential 
practice, as well as the first report targeting these disease 
states. A novel aspect of this project was the targeting of 
different subcategories of the “population health promoter” 
EPA domain. The HCV project effectively identified at-risk 
patients for the prevalent disease; the HSI project focused on 
minimizing hypoglycemic adverse events; the ASCVD project 
worked toward maximizing statin use within an at-risk 
population.  
When interpreting the number of screenings per month 
performed by each student pharmacist, it is important to note 
that students were generally present on site between four and 
six hours weekly. In addition to the time required for patient 
workup and telephone interactions, students spent time 
documenting encounters and discussing clinical aspects of 
patient care with the clinical pharmacist preceptor. While 
projects in this report made fewer interventions and saved 
less pharmacist time compared to the Cannon et al study, the 
scale of the work was smaller in terms of the number of 
student pharmacists (3 versus 46 students) and duration (3 to 
7 months versus nearly 4 years).11 Also, student pharmacists 
within the Cannon et al study devoted 50% to 60% of their 
APPE rotation time to PHM. In comparison, this report serves 
as a model for actively incorporating student pharmacists into 
PHM prior to full-time clinical rotations.  
 
Incorporation of student pharmacists into PHM offered 
several advantages to the student, clinic, and patient 
population. Due to the applicability of PHM to a variety of 
metrics within chronic disease states, each student took 
ownership of a project that matched their area of interest. 
Students gained hands-on experience in project development 
and management, had the opportunity to exercise written and 
verbal communication skills, and practiced clinical judgement 
outside of the classroom. These skillsets are essential in the 
preparation of students for APPEs and can help to facilitate 
student adjustment from didactic to practical training. 
Minimizing this adjustment period enables students to 
maximize time in their future clinical experiences, empowering 
them to become competent and capable pharmacists. Student 
involvement also enabled the pharmacist to expand clinical 
services. This partnership expanded patient care opportunities 
at the population level with many possible indirect benefits. 
For example, the education provided to patients may enhance 
health literacy, and the act of patient outreach may encourage 
engagement and improve satisfaction with care. 
 
These projects came with several limitations. Projects were 
conducted at a single institution where pharmacists have an 
advanced scope of practice. This model may not reflect the 
pharmacist’s role at other institutions, limiting generalizability 
to other practice sites. A second limitation was students’ 
varying levels of experience with the EHR prior to project 
implementation. When incorporating pre-APPE students into 
projects, resources for onboarding and training can limit 
feasibility; therefore, leveraging students familiar to the 
system can decrease the onboarding period.  
 
Future directions include incorporating PHM regularly into 
student pharmacist introductory pharmacy practice 
experience (IPPE) rotations. Since project materials have been 
developed and tested, future students can focus on screening 
and increase the efficiency and breadth of interventions. 
Future student PHM projects should incorporate formal 
student self-evaluations to promote awareness of perceived 
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changes in knowledge, skills, and abilities. Survey evaluation 
could occur at the start of APPE rotations to assess the impact 
of the student’s PHM experience on their ability to transition 
from didactic to practical training. Finally, measurement of the 
number of accepted recommendations and long-term clinical 
outcomes will quantify the impact of student led PHM 
projects.  
  
Conclusion  
Pharmacy education organizations have identified PHM as an 
area where new graduates should obtain the knowledge, skills, 
and abilities needed to successfully perform. This report 
highlights that pre-APPE student pharmacists can design and 
implement PHM projects and make significant impacts on the 
care of ambulatory patients. These projects demonstrate 
three unique disease states in which clinical pharmacists can 
engage students to expand clinical pharmacist impact. The 
novel endeavor can benefit students’ education and advance 
goals of the respective healthcare organization while striving 
for the triple aim of healthcare. 
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Table 1. Methodology of Student Population Health Management Projects 
 HCV Project^ HSI Project^^ ASCVD Project^^^ 
Duration, months 7 3 3 
Student Pharmacist 
Responsibilities 
• Performed chart reviews 
• Contacted patients 
• Educated patients on HCV 
prevalence, risks, and efficacy of 
current treatments 
• Ordered HCV and/or HIV antibody 
lab screenings 
• If unable to reach patients, left 
voicemails and mailed 
informational letters on HCV 
• Documented work in EHR 
• Performed chart reviews 
• Contacted patients 
• Conducted brief medication 
history and recorded blood 
glucose readings 
• Educated patients on signs and 
self-management of 
hypoglycemia* 
• Developed hypoglycemia 
prevention plan  
• Coordinated follow-up 
• Documented work in EHR 
• Performed chart reviews 
• Assessed need for statin 
therapy  
• Formulated statin therapy 
recommendation  
• Coordinated follow-up  
• Documented work in EHR 
Simplified Data 
Collection Process 
• Response to HCV/HIV screening 
• Labs: HCV and/or HIV antibody 
test result(s) 
• Informational letters sent 
• Telephone messages left 
• Terminal illness or life expectancy 
less than 6 months 
• Screened outside the VHA system 
(determined in EHR) 
• Age 
• Type of DM  
• Labs: SCr and A1c 
• DM medications 
• Presence of a beta blocker 
• SMBG (if available) 
• Diagnosis of cognitive 
impairment or dementia 
• Subjective or objective 
hypoglycemia reported 
• Education provided 
• Age 
• Body mass index 
• Labs: lipid profile 
• 10-year ASCVD risk**  
• History of DM or hypertension 
• Family history of ASCVD 
• Statin use history 
• Smoking history 
Inclusion Criteria HCV antibody screen: 
• Born from 1945 to 1965 with 
undocumented HCV status 
• Upcoming lab appointment 
 
HIV antibody screen: 
• Patients eligible for HCV screening 
with undocumented HIV status  
• Prescribed sulfonylurea or 
insulin 
• Most recent A1c <7% 
• At least 1 of the following: 
• Age >74 years 
• SCr >1.7 mg/dL 
• Diagnosed dementia or cognitive 
impairment 
• 40-75 years old 
• 10-year ASCVD risk ≥7.5% 
• LDL >70 mg/dL 
 
Exclusion Criteria • Documented terminal illness or 
life expectancy <6 months 
• Previously screened outside the 
VHA system 
• Unable to contact 
• Admitted to a long term care or 
inpatient facility 
• No A1c or Scr measured within 
the last 18 months 
• Unable to contact  
• History of ASCVD 
• LDL<70 mg/dL 
A1c=Hemoglobin A1c; ACC=American College of Cardiology; AHA=American Heart Association; ASCVD=atherosclerotic cardiovascular disease; 
DM=diabetes mellitus; EHR=electronic health record; HCV=hepatitis C virus; HIV=human immunodeficiency virus; HSI= hypoglycemia safety 
initiative; LDL=low density lipoproteins; SCr=serum creatinine; SMBG=self-monitoring of blood glucose; VHA= Veterans Health Administration.  
*Hypoglycemia is defined as self -monitored blood glucose readings <70 mg/dL.  
**Accessed at http://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/.  
Guidelines utilized for project development:  
^ Smith BD, Morgan RL, Beckett GA, et al; Recommendations for the identification of chronic hepatitis C virus infection among persons born during 
1945-1965. MMWR Recomm Rep. 2012;61(RR-4):1-32.  
^^ U.S. Department of Veterans Affairs/U.S. Department of Defense. VA/DoD clinical practice guideline for the management of type 2 diabetes 
mellitus in primary care. 2017:1-160. https://www.healthquality.va.gov/guidelines/CD/diabetes/VADoDDMCPGFinal508.pdf. Accessed May 15, 
2019.  
^^^Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic 
cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 
Circulation. 2014;129(25 Suppl 2):S1-S45. 
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Table 2. Interventions Provided by Student Pharmacists 
 HCV 
(n=110) 
HSI 
(n=25) 
ASCVD 
(n = 27) 
Total 
Number of Total Interventions, n 218 61 40 319 
Education, n (%) 110 (100) 22 (88) N/A 132 (97.8) 
Pharmacotherapy Recommendation, n (%)* 0 (0) 8 (32) 20 (74.1) 28 (17.2) 
Ambulatory Patient Monitoring, n (%) 107 (97.3) 25 (100) N/A 132 (97.8) 
Follow-up arranged, n (%) 1 (0.9) 6 (24) 20 (74.1) 27 (16.7) 
Patients assessed per month, mean 16 8 9 33 
Time committed per patient in minutes     
Preparation, mean  5 15 22 8.6 
Screening, mean  5 9.6 N/A 5.7 
ASCVD=atherosclerotic cardiovascular disease; HCV=hepatitis C virus; HSI=hypoglycemia safety initiative 
Note: percent for individual projects reflect total patients included in that project only 
 
 
 
 
Figure 1. Consort Diagram for Patient Inclusion and Exclusion 
 
*Excluded for not meeting inclusion criteria of respective projects in Table 1 
ASCVD=atherosclerotic cardiovascular disease; HCV=hepatitis C virus; HSI=hypoglycemia safety initiative 
